{"id":3837,"date":"2010-08-31T13:47:18","date_gmt":"2010-08-31T12:47:18","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=3837"},"modified":"2010-09-01T13:31:15","modified_gmt":"2010-09-01T12:31:15","slug":"james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/","title":{"rendered":"James Raftery on bevacizumab for metastatic colorectal cancer"},"content":{"rendered":"

Roche\u2019s bevacizumab (Avastin) is in the news again. This has a reasonable claim to be a wonder drug, but for macular degeneration, a disease for which Roche refuses to license it<\/a>. Instead Roche has tried and failed several times to have the drug recommended by NICE for lung, breast, and colorectal cancer, all at an extremely high price of around \u00a32k per month or \u00a324k per patient year.<\/p>\n

NICE considered and rejected<\/a> bevacizumab for metastatic colorectal cancer before in an appraisal that put the cost per QALY at \u00a357k to \u00a388k.<\/p>\n

The current appraisal consultation<\/a> document considers the use of bevacizumab as part of a new less restrictive oxaliplatin-containing combination of drugs for metastatic colorectal cancer.\u00a0Roche has kept the drug price at the same level as 2007. This led to a cost per QALY from \u00a3105k to \u00a3108k cost which Roche then\u00a0managed to reduce to \u00a324k to \u00a330k (depending on the combination therapy).<\/p>\n

How did Roche get the ICER down to \u00a324k to \u00a330k? By a patient access scheme<\/a> which has four elements: a) an upfront payment to the relevant NHS trust\u00a0(undisclosed amount) for each patient, b) free bevacizumab after 12 months, c) oxaliplatin provided free by Roche and d) bevacizumab to be purchased at full list price.<\/p>\n

Inclusion of a payment per patient is novel, amounting to a price discount. This\u00a0could be used to generate any cost per QALY one wanted. This payment seems to have been a late addition to the scheme (\u201cThe Committee reviewed the revised base case ICERs provided by the company \u2026which included an amendment to the patient access scheme of an additional upfront payment (designated by the manufacturer as commercial in confidence) of \u00a330,000 per QALY gained (\u00a3105k without the patient access scheme) for B-XELOX compared with XELOX\u2026.\u201dPara 4.11. XELOX refers to the drug combination, with and without Bevacizumab. \u00a324k per QALY refers to another drug combination FOLFOX)<\/p>\n

Patient access schemes have to be approved by the Department of Health. The department approved the scheme but expressed concerns<\/a> about its complexity which it considered might limit its uptake by the NHS and suggested the appraisal committee \u201cmay wish to be mindful.\u201d\u00a0\u00a0
\n\u00a0
\nThe appraisal committee considered that in the most plausible analysis bevacizumab offered no statistically significant gain in overall survival and a it only offered a gain in progression free survival of 1.4 months. It thus rejected it as a candidate for special consideration in terms of either end of life (not 3 months survival gain) or innovation (no step change).<\/p>\n

The appraisal committee was also not convinced<\/a> by Roche\u2019s economic model which generated a cost per QALYof \u00a330k, \u201cthe Comittee agreed that plausible adjustments to the key model inputs would increase these ICERs substantially\u201d<\/p>\n

Plausible adjustments included: patients were likely to continue to use bevacizumab longer than shown in the model, that the utility values for treatment were too high, that the cost of adverse events had not been included, and oxaliplatin has been mispriced.<\/p>\n

Roche\u2019s proposal to provide free supply of oxaliplatin, not one of its drugs, is also notable. The committee noted that Roche had priced oxaliplatin at its proprietary price not its generic price.<\/p>\n

What can one conclude from this?<\/p>\n

First that Roche has tried hard to get bevacizumab accepted by NICE at its current high list price. Besides colorectal cancer Roche initiated submissions to NICE for metastatic cancer of lung<\/a> and breast<\/a>, but its failure to submit evidence led to these appraisals being terminated in 2008. Its recent submission included a price discount nested within a patient access scheme, but the extent of the discount remains secret (commercial in confidence). Due to the inclusion of other elements in the patient access scheme it is not possible to readily deduce the price discount offered. However given that oxaliplatin is relatively low cost and that few if any patients will survive for 12 months, to reduce the cost per QALY from \u00a3105k to \u00a330k must have involved a price reduction of around two thirds.\u00a0\u00a0\u00a0\u00a0<\/p>\n

Second, despite this the appraisal committee seems to have rejected bevacizumab as first line treatment largely due to the relatively small gain in progression free survival of 1.4 months, with no proof of any gain in overall survival.<\/p>\n

Third the appraisal committee rejected the results of Roche\u2019s cost effectiveness model on the grounds of its unduly optimistic assumptions. This was a reasoned qualitative rather than a quantative judgement, since this was a single technology assessment in which cost per QALY was based solely on the Roche model.\u00a0\u00a0\u00a0<\/p>\n

Fourth, it remains to be seen if bevacizumab will qualify for the coalition government\u2019s cancer fund. If so it could quickly exhaust the fund. NICE\u2019s Technology Appraisal 117 put the number of new cases of metastatic colorectal cancer at 6-18k annually. At full cost of \u00a32k per month, this would amount to \u00a312 million to \u00a336 million for each month that patients were treated. However if Roche continues to offer the patient access scheme with the substantial price discount, the cost could be much less.\u00a0\u00a0\u00a0<\/p>\n

The bevacizumab story continues\u2026\u2026<\/p>\n

James Raftery<\/strong> is a health economist with several decades experience of the NHS. He is Professor of Health Technology Assessment at Southampton University. A keen \u2018NICE-watcher\u2019, he has provided economic input to technical assessment reports for NICE but has never been a member of any of its committees. The opinions expressed here are his personal views. Comments welcomed.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Roche\u2019s bevacizumab (Avastin) is in the news again. This has a reasonable claim to be a wonder drug, but for macular degeneration, a disease for which Roche refuses to license […]<\/p>\n

More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[915],"tags":[],"class_list":["post-3837","post","type-post","status-publish","format-standard","hentry","category-james-rafterys-nice-blogs"],"yoast_head":"\nJames Raftery on bevacizumab for metastatic colorectal cancer - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"James Raftery on bevacizumab for metastatic colorectal cancer - The BMJ\" \/>\n<meta property=\"og:description\" content=\"Roche\u2019s bevacizumab (Avastin) is in the news again. This has a reasonable claim to be a wonder drug, but for macular degeneration, a disease for which Roche refuses to license [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2010-08-31T12:47:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2010-09-01T12:31:15+00:00\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"James Raftery on bevacizumab for metastatic colorectal cancer\",\"datePublished\":\"2010-08-31T12:47:18+00:00\",\"dateModified\":\"2010-09-01T12:31:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/\"},\"wordCount\":905,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"articleSection\":[\"James Raftery's NICE blogs\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/\",\"name\":\"James Raftery on bevacizumab for metastatic colorectal cancer - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"datePublished\":\"2010-08-31T12:47:18+00:00\",\"dateModified\":\"2010-09-01T12:31:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2010\\\/08\\\/31\\\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"James Raftery on bevacizumab for metastatic colorectal cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"James Raftery on bevacizumab for metastatic colorectal cancer - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/","og_locale":"en_US","og_type":"article","og_title":"James Raftery on bevacizumab for metastatic colorectal cancer - The BMJ","og_description":"Roche\u2019s bevacizumab (Avastin) is in the news again. This has a reasonable claim to be a wonder drug, but for macular degeneration, a disease for which Roche refuses to license [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2010-08-31T12:47:18+00:00","article_modified_time":"2010-09-01T12:31:15+00:00","author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"James Raftery on bevacizumab for metastatic colorectal cancer","datePublished":"2010-08-31T12:47:18+00:00","dateModified":"2010-09-01T12:31:15+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/"},"wordCount":905,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"articleSection":["James Raftery's NICE blogs"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/","url":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/","name":"James Raftery on bevacizumab for metastatic colorectal cancer - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"datePublished":"2010-08-31T12:47:18+00:00","dateModified":"2010-09-01T12:31:15+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2010\/08\/31\/james-raftery-on-bevacizumab-for-metastatic-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"James Raftery on bevacizumab for metastatic colorectal cancer"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/3837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=3837"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/3837\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=3837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=3837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=3837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}